Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide renal and cardiovascular outcomes study in Chinese adults with type 2 diabetes mellitus and chronic kidney disease
CTR20263525Phase 4Active
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by Novo Nordisk. Started Sep 2026; status: active.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20263525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263525.